Noninferiority (NI) phase III trials in oncology: What is the basis for choosing the NI margin?

被引：0
|
作者：
Militao, M. S. [1 ]
Saad, E. D. [1 ]
机构：
[1] Dendrix Res, Sao Paulo, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e13070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13070
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response
    Zhou, Jie
    Jiang, Xun
    Xia, Hong Amy
    Wei, Peng
    Hobbs, Brian P.
    STATISTICS IN MEDICINE, 2022, 41 (04) : 751 - 768
  • [42] Designing phase III or IV trials for vaccines: Choosing between individual or cluster randomised trial designs
    Vaucher, Paul
    VACCINE, 2009, 27 (13) : 1928 - 1931
  • [43] HCV registries: what have we learned beyond the phase III trials
    Nelson, D.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 : 1 - 1
  • [44] What is an Adequate Radiation Therapy Quality Assuracne in Phase III Clinical Trials?
    Niazi, M. Tamim
    Parulekar, Wendy
    Parliament, Mathew
    Brundage, Michael
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (01): : 111 - 112
  • [45] Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology
    Sherry, Alexander D.
    Msaouel, Pavlos
    Kupferman, Gabrielle S.
    Lin, Timothy A.
    Jaoude, Joseph Abi
    Kouzy, Ramez
    Mccaw, Zachary R.
    Ludmir, Ethan B.
    van Zwet, Erik
    JCO PRECISION ONCOLOGY, 2024, 8
  • [46] Expected benefits versus actual outcomes in oncology phase III randomized controlled trials (RCTs).
    Gan, H. K.
    You, B.
    Pond, G. R.
    Chen, E. X.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Phase III Clinical Trials in Oncology - 20-21 January 2003, London, UK
    Buyse, M
    IDRUGS, 2003, 6 (03) : 187 - 190
  • [48] Adequacy of data provision and analysis in oncology phase III trials over the past 5 years
    Gan, H. K.
    You, B.
    Pond, G. R.
    Chen, E. X.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] Adverse events reporting in phase III oncology clinical trials of checkpoint inhibitors: A systematic review
    Joulia, M-L.
    Barhli, A.
    Tournigand, C.
    Kempf, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S725 - S725
  • [50] Speed of accrual into published phase III oncology trials: A comparison across geographic locations.
    Ruther, Nancy R.
    Jumonville, Alcee
    Mathiason, Michelle A.
    Emmel, Ann E.
    Wee, Sandra K.
    Go, Ronald S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345